MCID: ANG015
MIFTS: 58

Angioedema malady

Categories: Genetic diseases, Skin diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Angioedema

About this section

Aliases & Descriptions for Angioedema:

Name: Angioedema 10 47 12 36 65
Angioneurotic Oedema 10
Angioneurotic Edema 10
 
Giant Urticaria 10
Quincke's Edema 10

Classifications:



External Ids:

Disease Ontology10 DOID:1558
ICD1027 T78.3
MeSH36 D000799
NCIt42 C112175
UMLS65 C0002994

Summaries for Angioedema

About this section
Disease Ontology:10 A skin disease characterized by the rapid swelling of the dermis, subcutaneous tissue, mucosa and submucosal tissues.

MalaCards based summary: Angioedema, also known as angioneurotic oedema, is related to hereditary angioedema and acquired angioedema, and has symptoms including oropharyngeal swelling, mouth swelling and lip swelling. An important gene associated with Angioedema is SERPING1 (Serpin Family G Member 1), and among its related pathways are Protein digestion and absorption and Cell adhesion_Plasmin signaling. The drug fluoxymesterone has been mentioned in the context of this disorder. Affiliated tissues include skin, heart and breast, and related mouse phenotype homeostasis/metabolism.

Wikipedia:68 Angioedema, also known as angiooedema, Quincke\'s edema, and angioneurotic edema, is the rapid swelling... more...

Related Diseases for Angioedema

About this section

Diseases in the Angioedema family:

Angioedema, Hereditary, Type Iii Angioedema, Hereditary, Types I and Ii
Hereditary Angioedema Acquired Angioedema
Hereditary Angioedema Type 2 Acquired Angioedema Type 1
Acquired Angioedema Type 2

Diseases related to Angioedema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 188)
idRelated DiseaseScoreTop Affiliating Genes
1hereditary angioedema12.5
2acquired angioedema12.3
3angioedema, hereditary, type iii12.2
4angioedema induced by ace inhibitors12.2
5angioedema, hereditary, types i and ii12.1
6hereditary angioedema type 212.0
7acquired angioedema type 212.0
8renin-angiotensin-aldosterone system-blocker-induced angioedema11.9
9acquired angioedema type 111.8
10c1 inhibitor deficiency11.6
11vibratory urticaria11.2
12acquired fructose intolerance10.7C1S, SERPING1
13alopecia antibody deficiency10.7C1S, SERPING1
14follicular dendritic cell sarcoma10.7KNG1, SERPING1
15coxa vara, congenital10.6ACE, KNG1
16malignant hypertension10.6ACE, KNG1
17chromosome 9p deletion syndrome10.5ACE, SERPING1
18urticaria10.5
19autoimmune disease of central nervous system10.5F12, KNG1, SERPING1
20geotrichosis10.5CRP, F12
21intravascular fasciitis10.4CRP, F12
22cerebral lipidosis10.4ACE, KNG1
23diphtheria10.4CPN1, CRP
24retinal arteries, tortuosity of10.4ACE, APP
25personality disorder10.4APP, MME
26pulmonary aspergilloma10.4ACE, CRP
27narcissistic personality disorder10.4CPN1, CRP
28hypocomplementemic urticarial vasculitis syndrome10.4
29malignant parietal pleura tumor10.4CRP, MME
30ischemic optic neuropathy10.3ACE, CRP
31oral squamous cell carcinoma10.3ACE, CRP
32focal labyrinthitis10.3ACE, CRP
33primary non-gestational choriocarcinoma of ovary10.3ACE, AGTR2
34posterior valve urethra10.3ACE, AGTR2
35oral mucosa leukoplakia10.3ACE, CRP
36gonadal disease10.2ACE, CRP
37eosinophilia10.2
38syndactyly10.2PLG, SERPING1
39bronchus cancer10.2CRP, DPP4
40megakaryocytic leukemia10.2C1S, MME
41congenital chloride diarrhea10.2ACE, CRP, KNG1
42lymphoma10.1
43laryngitis10.1
44atrial heart septal defect10.1ACE, CRP, KNG1
45neuroretinitis10.1ACE, CRP
46tick-borne relapsing fever10.1PLG, SERPING1
47craniorachischisis10.1ACE, CRP, KNG1
48neonatal diabetes mellitus10.1CRP, DPP4
49diarrhea10.0APP, CRP
50dentin caries10.0CRP, DPP4

Graphical network of the top 20 diseases related to Angioedema:



Diseases related to angioedema

Symptoms for Angioedema

About this section

UMLS symptoms related to Angioedema:


oropharyngeal swelling, mouth swelling, lip swelling, edema of mouth, welts, joint swelling, periorbital edema

Drugs & Therapeutics for Angioedema

About this section

Drugs for Angioedema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 165)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
ZincapprovedPhase 414777440-66-623994, 32051
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
2
Omalizumabapproved, investigationalPhase 4, Phase 3, Phase 2137242138-07-4
Synonyms:
242138-07-4
D05251
Ig gamma-1 chain C region
Omalizumab
 
Omalizumab (USAN/INN)
Omalizumab (genetical recombination)
Omalizumab (genetical recombination) (JAN)
Xolair
Xolair (TN)
3
Histamine PhosphateapprovedPhase 4, Phase 3, Phase 290651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
4
RamiprilapprovedPhase 414487333-19-55362129
Synonyms:
(2 S ,3 aS ,6 aS )-1[( S )-N-[( S )-1-Carboxy-3-phenylpropyl] alanyl] octahydrocyclopenta [ b ]pyrrole-2-carboxylic acid, 1-ethyl ester
(2S,3aS,6aS)-1-((S)-2-((S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-((S)-N-((S)-1-Carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester
(2S,3aS,6aS)-1-((S)-N-((S)-1-Ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure
(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2H-cyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
(2S,3aS,6aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name)
(2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid.
(2S-(1(R*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid
(2s,3as,6as)-1((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic
(2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl)-octahydrocyclopenta[b]p
(2s,3as,6as)-1-[(s)-2-((s)-1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]
126613-39-6
87333-19-5
AC-1347
AC1NSFPR
Acovil
Almirall Brand of Ramipril
Altace
Altace (TN)
Altace (tn)
Astra Brand of Ramipril
AstraZeneca Brand of Ramipril
Aventis Brand of Ramipril
Aventis Pharma Brand of Ramipril
BIDD:GT0803
BSPBio_003347
Bio-0651
C23H32N2O5
CHEBI:289203
CHEBI:8774
CHEMBL1168
CID5362129
CPD000466386
Carasel
Cardace
D00421
D017257
DB00178
Delix
HMS2051E04
HMS2090L11
HMS2093M10
HOE 498
HOE498
Hoe-498
Hoechst Brand of Ramipril
 
Hypren
Hytren
KBio2_002504
KBio2_005072
KBio2_007640
KBio3_002849
KBioGR_001858
KBioSS_002512
LS-58199
Lostapres
MLS000759523
MLS001216547
MLS001423965
MolPort-001-736-571
Monarch Brand of Ramipril
N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid
NCGC00178127-01
Naprix
Pramace
Pramace (discontinued)
Promed Brand of Ramipril
Quark
R0404_SIGMA
Ramace
Ramipril
Ramipril (USP/INN)
Ramipril [USAN:INN:BAN]
Ramiprilum
Ramiprilum [Latin]
Ramipro, Tritace, Altace, Prilace, Ramipril
S1793_Selleck
SAM001246757
SAM002699899
SMR000466386
SPECTRUM1505214
STK801937
Spectrum3_001794
Spectrum4_001269
Spectrum5_001721
Spectrum_001958
Triatec
Tritace
UNII-L35JN3I7SJ
Unipril
Vesdil
Zabien
[2S,3aS,6aS]-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid
[2s,3as,6as]-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopen
ramipril
5
Sirolimusapproved, investigationalPhase 4179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
6
EnalaprilapprovedPhase 411275847-73-35362032, 40466924
Synonyms:
(2S)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
(S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
75847-73-3
AC1NTUS5
Analapril
BIDD:GT0751
BPBio1_000340
BSPBio_000308
BSPBio_003035
Bonuten
C06977
CAS-76095-16-4
CHEBI:116847
CHEBI:4784
CHEMBL578
CID5388962
D07892
DivK1c_000408
Enalapril
Enalapril (INN)
Enalapril (TN)
Enalapril Bp
Enalapril Maleate
Enalapril Richet
Enalaprila
Enalaprila [INN-Spanish]
Enalaprilat
Enalaprilum
 
Enalaprilum [INN-Latin]
Gadopril
HMS2090E08
IDI1_000408
KBio1_000408
KBio2_001787
KBio2_004355
KBio2_006923
KBio3_002535
KBioGR_000355
KBioSS_001787
Kinfil
LS-190651
MolPort-002-885-877
N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline
N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline
NCGC00016932-01
NCGC00021569-04
NCGC00021569-05
NCGC00021569-06
NINDS_000408
Prestwick3_000314
SPBio_001349
Spectrum2_001455
Spectrum3_001478
Spectrum4_000008
Spectrum5_001107
Spectrum_001307
Vaseretic
Vasotec
Vasotec IV
enalapril
7
Desloratadineapproved, investigationalPhase 469100643-71-8124087
Synonyms:
100643-71-8
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-Chloro-6,11-dihydro-11-(4-piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
8-chloro-11-(piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine
AC-1279
AC1L3XUD
AKOS000280921
Aerius
Allex
Azomyr
BB_SC-2104
C121345
CHEBI:291342
CHEMBL1172
CID124087
CPD000149358
Claramax
Clarinex
Clarinex (TN)
Clarinex RediTabs
Clarinex Reditabs
D03693
D3787
DB00967
DESLORATADINE
Denosin
Desalex
Descarboethoxyloratadine
Descarboethoxyoratidine
 
Desloratadine
Desloratadine (USAN/INN)
Desloratadine [USAN]
Desloratidine
Essex brand of desloratadine
HMS2052H05
HMS2090C06
HMS2093F19
I06-1866
L001025
LS-181814
MLS000559042
MLS000759406
MLS001201801
MolPort-000-883-875
NCGC00159325-02
NCGC00159325-03
NCGC00159325-04
NSC675447
NeoClarityn
Neoclarityn
Opulis
SAM001246545
SMR000149358
STK586537
Sch 34117
Sch-34117
Schering brand of desloratadine
Schering-Plough brand of desloratadine
TL8000065
UNII-FVF865388R
desloratadine
8
IcatibantapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 016138614-30-9, 130308-48-471364
Synonyms:
(2S)-2-[[(3aS,7aS)-1-[2-[(2S)-2-[[(2S)-2-[[2-[[(4R)-1-[1-[2-[[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]-4-hydroxypyrrolidine-2-carbonyl]amino]acetyl]amino]-3-thiophen-2-ylpropanoyl]amino]-3-hydroxypropanoyl]-3,4-dihydro-1H-isoquinoline-3-carbonyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid
(2s)-2-({[(3as,7as)-1-({2-[(2s)-2-{[(2s)-2-({[({(4r)-1-[(1-{2-({(2r)-2-amino-5-[(diaminomethylidene)amino]pentanoyl}amino)-5-[(diaminomethylidene)amino]pentanoyl}pyrrolidin-2-yl)carbonyl]-4-hydroxypyrrolidin-2-yl}carbonyl)amino]acetyl}amino)-3-(thiophen-2-yl)propanoyl]amino}-3-hydroxypropanoyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}carbonyl)octahydro-1h-indol-2-yl]carbonyl}amino)-5-[(diaminomethylidene)amino]pentanoic acid(non-preferred name)
130308-48-4
138614-30-9 (acetate)
13996-86-6
153322-84-0
AC1L2G0Q
AC1Q5QRX
AR-1A3141
C59H89N19O13S
CHEBI:163731
CHEMBL411169
CID71364
 
D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK
DB06196
Firazyr
HOE 140
HOE140
Hoe-140
Icatibant
Icatibant Acetate
Icatibant [INN]
JE049
KST-1A1301
LS-172762
WIN 65365
WIN-65365
9
EverolimusapprovedPhase 41797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
10
Valsartanapproved, investigationalPhase 4268137862-53-460846
Synonyms:
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
137862-53-4
AC-4543
AC1L1U1M
AC1Q5QIK
Ambap137862-53-4
Aventis brand of valsartan
BIDD:GT0345
BRD-K45158365-001-02-3
BSPBio_003501
Bio-0796
C081489
C24H29N5O3
CEPA brand of valsartan
CGP 48933
CGP-48933
CHEBI:9927
CHEMBL1069
CID60846
CPD000466318
D00400
DB00177
Diovan
Diovan (TN)
Diovan, Valsartan
Esteve brand of valsartan
HMS1922L21
HMS2051L12
HMS2093K22
HSDB 7519
KBio2_002287
KBio2_004855
KBio2_007423
KBio3_003006
KBioGR_001078
KBioSS_002289
Kalpress
 
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
LS-161334
Lacer brand of valsartan
MLS000759423
MLS001424088
Miten
MolPort-002-507-854
MolPort-003-666-608
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-Pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
Nisis
Nisis||
Novartis brand of valsartan
Provas
S1894_Selleck
SAM001246581
SMR000466318
SPBio_001260
SPECTRUM1505209
Sanol brand of valsartan
Schwarz brand of valsartan
Spectrum2_001120
Spectrum3_001831
Spectrum4_000749
Spectrum5_001582
Spectrum_001796
TL8000869
Tareg
UNII-80M03YXJ7I
Vals
Valsarran
Valsartan
Valsartan (JAN/USAN/INN)
Valsartan [USAN:INN]
valsartan
walsartan
|Tareg
11Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 08496
12Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 3, Phase 2, Phase 1, Phase 03549
13Complement System ProteinsPhase 4, Phase 3, Phase 2, Phase 1, Phase 0190
14Protease InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 04558
15Cholinergic AntagonistsPhase 41423
16HIV Protease InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 04558
17
BradykininPhase 4, Phase 3, Phase 2, Phase 1, Phase 04758-82-2439201
Synonyms:
Callidin I
Kallidin 9
 
Kallidin I
L-Arginyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-seryl-L-prolyl-L-phenylalanyl-L-Arginine
L-Bradykinin
18Angiotensin-Converting Enzyme InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 0634
19Antihypertensive AgentsPhase 4, Phase 2, Phase 33618
20Anti-Inflammatory AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 08478
21Histamine H1 Antagonists, Non-SedatingPhase 4, Phase 2323
22
EnalaprilatPhase 411276420-72-96917719
Synonyms:
(2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-2-[[(2S)-1-hydroxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]pyrrolidine-2-carboxylic acid dihydrate
1-((2S)-2-{[(1S)-1-CARBOXY-3-PHENYLPROPYL]AMINO}PROPANOYL)-L-PROLINE
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
76420-72-9
AC1NUWEA
AC1OCEK7
BIDD:GT0752
C11720
C18H24N2O5.2H2O
CHEBI:116759
CHEBI:42302
CHEBI:4786
CHEBI:59877
CHEMBL1200697
CHEMBL577
CID5462501
CID6917719
CPD000466359
D03769
EAL
ENALAPRILAT INHIBITOR
Enalapril acid
Enalapril diacid
 
Enalaprilat
Enalaprilat (USP)
Enalaprilat anhydrous
Enalaprilate
Enalaprilatum
Enalaprilic acid
Enalprilate hydrate
HMS2051H16
HMS2089P04
LS-118903
LS-187219
MK-422
MLS000759476
MLS001424138
MolPort-005-943-792
N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl-L-proline
N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline
N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-L-proline--water (1/2)
NCGC00164593-01
S1657_Selleck
SAM001246684
SBB065733
SMR000466359
Vasotec I.V.
enalprilat hydrate
23LCZ 696Phase 4, Phase 236
24AnalgesicsPhase 4, Phase 3, Phase 2, Phase 1, Phase 09358
25Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 2, Phase 1, Phase 05184
26AngiotensinogenPhase 4, Phase 2, Phase 31032
27
Angiotensin IIPhase 4, Phase 2, Phase 3103368521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
28Angiotensin II Type 1 Receptor BlockersPhase 4, Phase 2, Phase 3949
29Angiotensin Receptor AntagonistsPhase 4, Phase 2, Phase 31039
30Insulin, Globin ZincPhase 44278
31Cholinergic AgentsPhase 43243
32Complement C1 Inhibitor ProteinPhase 4, Phase 3, Phase 2, Phase 142
33Complement C1sPhase 4, Phase 3, Phase 2, Phase 130
34AntibodiesPhase 4, Phase 3, Phase 14477
35ImmunoglobulinsPhase 4, Phase 3, Phase 14477
36Complement C1 Inactivator ProteinsPhase 4, Phase 3, Phase 2, Phase 139
37Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018510
38Complement Inactivating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 071
39insulinPhase 44278
40Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 010422
41KininogensPhase 4, Phase 3, Phase 2, Phase 1, Phase 047
42Anti-Allergic AgentsPhase 4, Phase 3, Phase 21312
43Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018483
44Respiratory System AgentsPhase 4, Phase 3, Phase 23931
45Hypoglycemic AgentsPhase 44503
46Anti-Asthmatic AgentsPhase 4, Phase 3, Phase 22796
47Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 114795
48Bradykinin B2 Receptor AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Phase 013
49Bradykinin Receptor AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Phase 017
50Histamine H1 AntagonistsPhase 4, Phase 3, Phase 2688

Interventional clinical trials:

(show top 50)    (show all 111)
idNameStatusNCT IDPhase
1Efficacy, Safety and Tolerability of a Self-Administered Subcutaneous Formulation of Icatibant for the Treatment of Acute Attacks of Hereditary AngioedemaCompletedNCT01457430Phase 4
2A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZECompletedNCT00914966Phase 4
3Postmarketing Immunogenicity Study in HAE Subjects Treated With BerinertCompletedNCT01467947Phase 4
4Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE TreatmentCompletedNCT02550106Phase 4
5Exubera Large Simple Trial To Evaluate Long-Term Pulmonary And Cardiovascular SafetyCompletedNCT00359801Phase 4
6Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To SirolimusCompletedNCT00502242Phase 4
7Desloratadine 5, 10 and 20mg in Patients With Cold UrticariaCompletedNCT01444196Phase 4
8comParIson Of Sacubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure EpisodeRecruitingNCT02554890Phase 4
9A Call Center During HAE Attacks (SOS HAE)Active, not recruitingNCT01679912Phase 4
10C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) ExacerbationWithdrawnNCT01151735Phase 4
11A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaCompletedNCT01912456Phase 3
12C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) AngioedemaCompletedNCT00125151Phase 3
13C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) AngioedemaCompletedNCT00125541Phase 2, Phase 3
14Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary AngioedemaCompletedNCT00097695Phase 3
15Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to TherapyCompletedNCT01723072Phase 3
1612-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksCompletedNCT02303626Phase 2, Phase 3
17Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced AngioedemaCompletedNCT01919801Phase 3
18Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00438815Phase 3
19Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262301Phase 3
20Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00225147Phase 2, Phase 3
21Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE AttacksCompletedNCT01188564Phase 3
22Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00462709Phase 3
23A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)CompletedNCT00912093Phase 3
24Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)CompletedNCT00456508Phase 3
25Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00457015Phase 3
26C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT01005888Phase 3
27Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00500656Phase 3
28C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)CompletedNCT00292981Phase 3
29Berinert P Study of Subcutaneous Versus Intravenous AdministrationCompletedNCT00748202Phase 3
30Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262288Phase 2, Phase 3
31Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)CompletedNCT00262080Phase 3
32C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) AttacksCompletedNCT00289211Phase 3
33Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) AttacksCompletedNCT00168103Phase 2, Phase 3
34EASSI - Evaluation of the Safety of Self-Administration With IcatibantCompletedNCT00997204Phase 3
35AVE7688 in Patients With Mild to Moderate Blood PressureCompletedNCT00284128Phase 2, Phase 3
36A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)CompletedNCT01292473Phase 3
37A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) TreatmentCompletedNCT01287117Phase 3
38A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor AntagonistsCompletedNCT01264939Phase 3
39Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in EmergencyCompletedNCT02565680Phase 2, Phase 3
40Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary AngioedemaRecruitingNCT02052141Phase 3
41Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAERecruitingNCT02586805Phase 3
42Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaRecruitingNCT02584959Phase 3
43Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced AngioedemaRecruitingNCT01843530Phase 3
44OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) PatientsRecruitingNCT02161562Phase 3
45Bilastine Updosing in Chronic Spontaneous UrticariaRecruitingNCT02213367Phase 3
46Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus InfectionRecruitingNCT02365493Phase 3
47A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary AngioedemaActive, not recruitingNCT01386658Phase 3
48A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary AngioedemaActive, not recruitingNCT02316353Phase 3
49Long-term Safety and Efficacy Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAEEnrolling by invitationNCT02741596Phase 3
50Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary AngioedemaTerminatedNCT02670720Phase 3

Search NIH Clinical Center for Angioedema

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: angioedema

Genetic Tests for Angioedema

About this section

Anatomical Context for Angioedema

About this section

MalaCards organs/tissues related to Angioedema:

33
Skin, Heart, Breast, Brain, Liver, Prostate, Bone

Animal Models for Angioedema or affiliated genes

About this section

MGI Mouse Phenotypes related to Angioedema:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053766.5ACE, AGTR2, APP, BDKRB2, CRP, DPP4

Publications for Angioedema

About this section

Articles related to Angioedema:

(show top 50)    (show all 1206)
idTitleAuthorsYear
1
Drug-induced non-immune-mediated angioedema. (27152403)
2016
2
First report of icatibant treatment in a pregnant patient with hereditary angioedema. (27093898)
2016
3
Prophylaxis in hereditary angioedema (HAE) with C1 inhibitor deficiency. (26972189)
2016
4
Lingual angioedema after alteplase treatment in a patient with acute ischemic stroke. (25802571)
2015
5
Hereditary angioedema: Molecular and clinical differences among European populations. (25258140)
2014
6
Prognostic factors in outcome of angioedema in the emergency department. (25295803)
2014
7
Characterization of a partial exon 9/intron 9 deletion in the coagulation factor XII gene (F12) detected in two Turkish families with hereditary angioedema and normal C1 inhibitor. (25113305)
2014
8
Anaphylaxis/angioedema caused by honey ingestion. (24433600)
2014
9
Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. (24468257)
2014
10
Depression and anxiety in patients with hereditary angioedema. (24428960)
2013
11
The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin. (23972359)
2013
12
Hereditary angioedema: epidemiology, management, and role of icatibant. (23662043)
2013
13
Onset of Orolingual Angioedema After Treatment of Acute Brain Ischemia with Alteplase Depends on the Site of Brain Ischemia: A Meta-analysis. (24350070)
2013
14
Diagnosing angioedema. (24176210)
2013
15
The burden of illness in patients with hereditary angioedema. (24125136)
2013
16
Recent advances in hereditary angioedema self-administration treatment: summary of an International Hereditary Angioedema Expert Meeting. (23689237)
2013
17
Practical algorithm for diagnosing patients with recurrent wheals or angioedema. (23646863)
2013
18
The role of ficolins and MASPs in hereditary angioedema due to C1-inhibitor deficiency. (23318225)
2013
19
Management of hereditary angioedema in 2012: scientific and pharmacoeconomic perspectives. (23352523)
2013
20
Hereditary angioedema: not an allergy. (23248378)
2012
21
Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema. (22149337)
2012
22
Hereditary angioedema: short-term prophylaxis for surgery. (22856630)
2012
23
Efficacy assessments in randomized controlled studies of acute therapy for hereditary angioedema. (22797816)
2012
24
Type III hereditary angioedema: defined, but not understood. (22920066)
2012
25
Successful C1 esterase inhibitor therapy in a child with a novel type 3 hereditary angioedema-like syndrome. (22626603)
2012
26
Hereditary angioedema: a survey of UK emergency departments and recommendations for management. (22008588)
2012
27
Isolated angioedema of the bowel due to C1 esterase inhibitor deficiency: a case report and review of literature. (21320328)
2011
28
Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. (20477917)
2011
29
Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism. (23282868)
2010
30
Pathogenesis and laboratory diagnosis of hereditary angioedema. (19843402)
2009
31
Icatibant for hereditary angioedema. (20135020)
2009
32
Acute edema blisters in a hereditary angioedema cutaneous attack. (18680708)
2008
33
Orolingual angioedema as complication after rt-PA in stroke patient treated with ACE inhibitor]. (18453163)
2008
34
Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. (18320917)
2008
35
Treatment of hereditary angioedema with plasma-derived C1 inhibitor. (19209279)
2008
36
Hereditary angioedema: new hopes for an orphan disease. (19160940)
2008
37
Not all ACE inhibitor related angioedema is always evident: a case which is misdiagnosed as panic attack and speech disorder. (18047821)
2007
38
Haploinsufficiency due to deletion within the 3'-UTR of C1-INH-gene associated with hereditary angioedema. (16617246)
2006
39
Episodic macroglossia as the sole manifestation of angiotensin-converting enzyme inhibitor-induced angioedema. (15053206)
2004
40
Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. (15111379)
2004
41
Rapid detection by fluorescent multiplex PCR of exon deletions and duplications in the C1 inhibitor gene of hereditary angioedema patients. (11139243)
2001
42
Angioedema due to losartan. (10492494)
1999
43
Angioedema due to ACE inhibitors: increased risk in patients of African origin. (10594491)
1999
44
ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema. (9793599)
1998
45
Human parvovirus infection: rheumatic manifestations, angioedema, C1 esterase inhibitor deficiency, ANA positivity, and possible onset of systemic lupus erythematosus. (8823689)
1996
46
Hereditary angioedema. Description of a pediatric case]. (1791801)
1991
47
Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction. (2233075)
1990
48
Allergic urticaria and hereditary angioedema. Independent association in the same patient. (6509770)
1984
49
50

Variations for Angioedema

About this section

Expression for genes affiliated with Angioedema

About this section
Search GEO for disease gene expression data for Angioedema.

Pathways for genes affiliated with Angioedema

About this section

Pathways related to Angioedema according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.4DPP4, MME, XPNPEP2
29.4F12, PLG, SERPING1
39.4ACE, APP, MME
4
Show member pathways
9.1F12, KNG1, PLG, SERPING1
5
Show member pathways
9.0ACE, CPN1, DPP4, MME
6
Show member pathways
8.8ACE, AGTR2, BDKRB2, KNG1, MME
78.7ACE, APP, MME, PLG
8
Show member pathways
8.6APP, F12, KNG1, PLG, SERPING1
9
Show member pathways
8.4BDKRB2, C1S, F12, KNG1, PLG, SERPING1

GO Terms for genes affiliated with Angioedema

About this section

Cellular components related to Angioedema according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1blood microparticleGO:00725629.3C1S, PLG, SERPING1

Biological processes related to Angioedema according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1positive regulation of fibrinolysisGO:005191910.2F12, PLG
2blood vessel remodelingGO:000197410.1ACE, AGTR2
3smooth muscle contractionGO:000693910.1BDKRB2, KNG1
4positive regulation of renal sodium excretionGO:003581510.0AGTR2, KNG1
5regulation of vasoconstrictionGO:00192299.9ACE, BDKRB2
6fibrinolysisGO:00427309.7F12, PLG, SERPING1
7proteolysisGO:00065089.0ACE, F12, PLG
8inflammatory responseGO:00069548.8AGTR2, CRP, KNG1

Molecular functions related to Angioedema according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1metallopeptidase activityGO:00082379.8ACE, XPNPEP2

Sources for Angioedema

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet